Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Tamborlane WV, et al. Among authors: hale pm. N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28. N Engl J Med. 2019. PMID: 31034184 Clinical Trial.
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. Kelly AS, et al. Among authors: hale pm. N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31. N Engl J Med. 2020. PMID: 32233338 Clinical Trial.
Liraglutide for Adolescents with Obesity. Reply.
Kelly AS, Hale PM. Kelly AS, et al. Among authors: hale pm. N Engl J Med. 2020 Sep 17;383(12):1193-1194. doi: 10.1056/NEJMc2023284. N Engl J Med. 2020. PMID: 32937058 No abstract available.
Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S; NN2211-1800 Study Group. Klein DJ, et al. Among authors: hale pm. Diabetes Technol Ther. 2014 Oct;16(10):679-87. doi: 10.1089/dia.2013.0366. Epub 2014 Jul 18. Diabetes Technol Ther. 2014. PMID: 25036533 Free PMC article. Clinical Trial.
Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC, Hale PM, Kordonouri O. Danne T, et al. Among authors: hale pm. J Pediatr. 2017 Feb;181:146-153.e3. doi: 10.1016/j.jpeds.2016.10.076. Epub 2016 Dec 13. J Pediatr. 2017. PMID: 27979579 Free article. Clinical Trial.
Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
Mastrandrea LD, Witten L, Carlsson Petri KC, Hale PM, Hedman HK, Riesenberg RA. Mastrandrea LD, et al. Among authors: hale pm. Pediatr Obes. 2019 May;14(5):e12495. doi: 10.1111/ijpo.12495. Epub 2019 Jan 17. Pediatr Obes. 2019. PMID: 30653847 Free PMC article. Clinical Trial.
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
44 results